Bromfenac Pregnancy and Breastfeeding Warnings
Brand names: DurAct
Bromfenac Pregnancy Warnings
Bromfenac has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of reduced embryo/fetal survival, dystocia, and delayed parturition. There are no controlled data in human pregnancy. Bromfenac is only recommended for use during pregnancy when the benefit outweighs risk. Because nonsteroidal anti-inflammatory drugs are known to delay parturition or cause premature closure of the ductus arteriosus, bromfenac should be avoided during late pregnancy.
Bromfenac Breastfeeding Warnings
There are no data on the excretion of bromfenac into human milk.
Bromfenac is excreted into the milk of lactating rats.
See also
References for pregnancy information
- "Product Information. DurAct (bromfenac)." Wyeth-Ayerst Laboratories
- Koren G, Pastuszak A, Ito S (1998) "Drugs in pregnancy." N Engl J Med, 338, p. 1128-37
References for breastfeeding information
- "Product Information. DurAct (bromfenac)." Wyeth-Ayerst Laboratories
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
